OA16854A - Levomilnacipran drug for functional rehabilitation after an acute neurological stroke - Google Patents
Levomilnacipran drug for functional rehabilitation after an acute neurological stroke Download PDFInfo
- Publication number
- OA16854A OA16854A OA1201400040 OA16854A OA 16854 A OA16854 A OA 16854A OA 1201400040 OA1201400040 OA 1201400040 OA 16854 A OA16854 A OA 16854A
- Authority
- OA
- OAPI
- Prior art keywords
- levomilnacipran
- dextromilnacipran
- mixture
- brain
- pharmaceutical compositions
- Prior art date
Links
- GJJFMKBJSRMPLA-DZGCQCFKSA-N Levomilnacipran Chemical compound C=1C=CC=CC=1[C@]1(C(=O)N(CC)CC)C[C@H]1CN GJJFMKBJSRMPLA-DZGCQCFKSA-N 0.000 title claims abstract description 45
- 229960000685 Levomilnacipran Drugs 0.000 title claims abstract description 43
- 230000000926 neurological Effects 0.000 title claims description 18
- 230000001154 acute Effects 0.000 title claims description 14
- 239000003814 drug Substances 0.000 title abstract description 10
- 229940079593 drugs Drugs 0.000 title abstract description 9
- GJJFMKBJSRMPLA-HIFRSBDPSA-N Milnacipran Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 claims abstract description 70
- 239000000203 mixture Substances 0.000 claims abstract description 38
- 208000006011 Stroke Diseases 0.000 claims abstract description 32
- 238000011084 recovery Methods 0.000 claims abstract description 29
- 206010008190 Cerebrovascular accident Diseases 0.000 claims abstract description 26
- 201000001084 cerebrovascular disease Diseases 0.000 claims abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 206010070976 Craniocerebral injury Diseases 0.000 claims description 15
- 208000005765 Traumatic Brain Injury Diseases 0.000 claims description 15
- 230000002792 vascular Effects 0.000 claims description 6
- 230000002354 daily Effects 0.000 claims description 3
- 239000000546 pharmaceutic aid Substances 0.000 claims description 3
- 230000031891 intestinal absorption Effects 0.000 claims description 2
- 208000008208 Craniocerebral Trauma Diseases 0.000 abstract 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 30
- 102000005962 receptors Human genes 0.000 description 28
- 108020003175 receptors Proteins 0.000 description 28
- 230000002401 inhibitory effect Effects 0.000 description 23
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 19
- 229960002748 Norepinephrine Drugs 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- 210000004556 Brain Anatomy 0.000 description 18
- 241000282414 Homo sapiens Species 0.000 description 17
- 201000010099 disease Diseases 0.000 description 16
- 229940076279 Serotonin Drugs 0.000 description 15
- 239000003112 inhibitor Substances 0.000 description 14
- 210000004027 cells Anatomy 0.000 description 12
- 229960000600 Milnacipran Drugs 0.000 description 11
- 102000008092 Norepinephrine Plasma Membrane Transport Proteins Human genes 0.000 description 11
- 108010049586 Norepinephrine Plasma Membrane Transport Proteins Proteins 0.000 description 11
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 11
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 11
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 229960002464 Fluoxetine Drugs 0.000 description 7
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- IENZQIKPVFGBNW-UHFFFAOYSA-N Prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 6
- 229960001289 Prazosin Drugs 0.000 description 6
- 230000003042 antagnostic Effects 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 230000001965 increased Effects 0.000 description 6
- 239000002287 radioligand Substances 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 229960003638 dopamine Drugs 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 210000001367 Arteries Anatomy 0.000 description 4
- 206010010071 Coma Diseases 0.000 description 4
- 206010018987 Haemorrhage Diseases 0.000 description 4
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 206010033799 Paralysis Diseases 0.000 description 4
- 239000000674 adrenergic antagonist Substances 0.000 description 4
- 230000001684 chronic Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000001537 neural Effects 0.000 description 4
- 238000000159 protein binding assay Methods 0.000 description 4
- 238000004088 simulation Methods 0.000 description 4
- 230000000472 traumatic Effects 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 208000006752 Brain Edema Diseases 0.000 description 3
- 206010048962 Brain oedema Diseases 0.000 description 3
- 208000005189 Embolism Diseases 0.000 description 3
- 206010018852 Haematoma Diseases 0.000 description 3
- 206010019468 Hemiplegia Diseases 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000001149 cognitive Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002610 neuroimaging Methods 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- -1 stéarate Chemical compound 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000001225 therapeutic Effects 0.000 description 3
- 210000001519 tissues Anatomy 0.000 description 3
- 230000001052 transient Effects 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- XNCDYJFPRPDERF-NQQJLSKUSA-N (1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide;hydrochloride Chemical compound Cl.C=1C=CC=CC=1[C@]1(C(=O)N(CC)CC)C[C@H]1CN XNCDYJFPRPDERF-NQQJLSKUSA-N 0.000 description 2
- BRZYSWJRSDMWLG-DJWUNRQOSA-N (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-[(1R)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 2
- QXWYKJLNLSIPIN-YUMQZZPRSA-N (2S,3S)-2-azaniumyl-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoate Chemical compound [O-]C(=O)[C@@H]([NH3+])[C@@H](O)C1=CC=C(O)C(O)=C1 QXWYKJLNLSIPIN-YUMQZZPRSA-N 0.000 description 2
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Adhd patch Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 2
- 102000017910 Adrenergic receptor family Human genes 0.000 description 2
- 108060003345 Adrenergic receptor family Proteins 0.000 description 2
- 208000007415 Anhedonia Diseases 0.000 description 2
- 206010002855 Anxiety Diseases 0.000 description 2
- 206010057666 Anxiety disease Diseases 0.000 description 2
- 206010003178 Arterial thrombosis Diseases 0.000 description 2
- 229940072107 Ascorbate Drugs 0.000 description 2
- 210000004369 Blood Anatomy 0.000 description 2
- 208000001183 Brain Injury Diseases 0.000 description 2
- 206010052346 Brain contusion Diseases 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- 206010010254 Concussion Diseases 0.000 description 2
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 2
- 208000001640 Fibromyalgia Diseases 0.000 description 2
- SFLSHLFXELFNJZ-MRVPVSSYSA-N L-Noradrenaline Natural products NC[C@@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-MRVPVSSYSA-N 0.000 description 2
- 101700048515 LEC1 Proteins 0.000 description 2
- 101700046135 LEC2 Proteins 0.000 description 2
- 208000001652 Memory Disorders Diseases 0.000 description 2
- 229960001344 Methylphenidate Drugs 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 description 2
- 229960001779 Pargyline Drugs 0.000 description 2
- CBQGYUDMJHNJBX-RTBURBONSA-N Reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 description 2
- 206010041466 Speech disease Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 201000007201 aphasia Diseases 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 230000001054 cortical Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000002939 deleterious Effects 0.000 description 2
- 229960003914 desipramine Drugs 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229960001104 droxidopa Drugs 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000002045 lasting Effects 0.000 description 2
- 230000003278 mimic Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 210000002569 neurons Anatomy 0.000 description 2
- 230000002474 noradrenergic Effects 0.000 description 2
- 230000012154 norepinephrine uptake Effects 0.000 description 2
- 230000000414 obstructive Effects 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229960003770 reboxetine Drugs 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000697 serotonin reuptake Effects 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010000370 Accident at home Diseases 0.000 description 1
- 229940022663 Acetate Drugs 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 208000006888 Agnosia Diseases 0.000 description 1
- 241001047040 Agnosia Species 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 206010003062 Apraxia Diseases 0.000 description 1
- 206010003119 Arrhythmia Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010003658 Atrial fibrillation Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010049848 Balance disease Diseases 0.000 description 1
- 208000007204 Brain Death Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006126 Brain herniation Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010007521 Cardiac arrhythmias Diseases 0.000 description 1
- 210000003737 Chromaffin Cells Anatomy 0.000 description 1
- 206010008874 Chronic fatigue syndrome Diseases 0.000 description 1
- WSEQXVZVJXJVFP-UHFFFAOYSA-N Citalopram Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 WSEQXVZVJXJVFP-UHFFFAOYSA-N 0.000 description 1
- 206010057668 Cognitive disease Diseases 0.000 description 1
- 208000008313 Contusions Diseases 0.000 description 1
- 208000004981 Coronary Disease Diseases 0.000 description 1
- 210000003792 Cranial Nerves Anatomy 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229940030606 DIURETICS Drugs 0.000 description 1
- 208000000264 Deglutition Disorders Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 230000036947 Dissociation constant Effects 0.000 description 1
- 208000002173 Dizziness Diseases 0.000 description 1
- 206010015769 Extradural haematoma Diseases 0.000 description 1
- 210000003414 Extremities Anatomy 0.000 description 1
- 206010061129 Eye movement disease Diseases 0.000 description 1
- 206010016059 Facial pain Diseases 0.000 description 1
- 206010016256 Fatigue Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 210000002532 Foramen Magnum Anatomy 0.000 description 1
- 108060003339 GPLD1 Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headache Diseases 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022114 Injury Diseases 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- 208000002551 Irritable Bowel Syndrome Diseases 0.000 description 1
- 206010061256 Ischaemic stroke Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 206010024855 Loss of consciousness Diseases 0.000 description 1
- 206010024870 Loss of libido Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010061284 Mental disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 229960000638 Milnacipran hydrochloride Drugs 0.000 description 1
- 208000008433 Motor Disorders Diseases 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 208000010125 Myocardial Infarction Diseases 0.000 description 1
- 102000004868 N-methyl-D-aspartate receptors Human genes 0.000 description 1
- 108090001041 N-methyl-D-aspartate receptors Proteins 0.000 description 1
- 206010029331 Neuropathy peripheral Diseases 0.000 description 1
- 206010062501 Non-cardiac chest pain Diseases 0.000 description 1
- 229940049964 Oleate Drugs 0.000 description 1
- 206010073261 Ovarian theca cell tumour Diseases 0.000 description 1
- 210000001672 Ovary Anatomy 0.000 description 1
- 206010033775 Paraesthesia Diseases 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- 229960001999 Phentolamine Drugs 0.000 description 1
- 206010036312 Post-traumatic epilepsy Diseases 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 210000001747 Pupil Anatomy 0.000 description 1
- 206010040984 Sleep disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000002667 Subdural Hematoma Diseases 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 210000001738 Temporomandibular Joint Anatomy 0.000 description 1
- 206010043269 Tension headache Diseases 0.000 description 1
- 208000008548 Tension-Type Headache Diseases 0.000 description 1
- 208000001644 Thecoma Diseases 0.000 description 1
- 102000003978 Tissue plasminogen activator Human genes 0.000 description 1
- 108090000373 Tissue plasminogen activator Proteins 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 241000958541 Vulpes zerda Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive Effects 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000695 adrenergic alpha-agonist Substances 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001396 anti-anti-diuretic Effects 0.000 description 1
- 230000003501 anti-edematous Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 230000001174 ascending Effects 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 230000003376 axonal Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000271 cardiovascular Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 108091006028 chimera Proteins 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005824 corn Nutrition 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 230000001808 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed Effects 0.000 description 1
- 230000001079 digestive Effects 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000534 elicitor Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000003480 fibrinolytic Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal Effects 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M laurate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 229960001926 levomilnacipran hydrochloride Drugs 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000051 modifying Effects 0.000 description 1
- 125000005487 naphthalate group Chemical group 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 210000004255 neuroglia Anatomy 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000000508 neurotrotrophic Effects 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000000966 norepinephrine reuptake Effects 0.000 description 1
- 201000005016 ocular motility disease Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-L oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 description 1
- 229940039748 oxalate Drugs 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M palmitate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002085 persistent Effects 0.000 description 1
- MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000001144 postural Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive Effects 0.000 description 1
- 230000002685 pulmonary Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000036362 sensorimotor function Effects 0.000 description 1
- 230000001953 sensory Effects 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 230000000392 somatic Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 201000010874 syndrome Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 229960000103 thrombolytic agents Drugs 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 231100000730 tolerability Toxicity 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-M valerate Chemical compound CCCCC([O-])=O NQPDZGIKBAWPEJ-UHFFFAOYSA-M 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- 201000011528 vascular disease Diseases 0.000 description 1
- 239000004562 water dispersible granule Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Abstract
The present invention relates to the use of levomilnacipran as a drug in functional recovery after a cerebrovascular accident or head trauma. The pharmaceutical compositions containing levomilnacipran are strictly those in which the levomilnacipran/dextromilnacipran mixture does not contain more than 5 wt % of dextromilnacipran, so as to not risk compromising functional recovery due to the alpha-blocking property of the dextromilnacipran.
Description
Levomilnacipran drug for functional réhabilitation after an acute neurological stroke.
DESCRIPTION
There are two types of acute neurological events leading to motor and cognitive déficit: one is of vascular origin i.e. a Cerebrovascular Accident , (stroke) and the other is of traumatic origin i.e. Traumatic Brain Injury.
According to WHO, a Cerebrovascular Accident (CVA) is rapidly developing clinical signs of focal (at times global) disturbance of cérébral function, lasting more than 24 hours or leading to death with no apparent cause other than that of vascular origin. The term brain attack is also used or apoplexy. CVA is to be distinguished from a transient ischémie attack (TIA) defined as sudden loss of cérébral or ocular function lasting less than 24 hours assumed to be due to an embolism or vascular thrombosis. CVA is the most frequent type of neurological disease: in Western countries it represents the third cause of death (after coronary diseases and cancers) and the leading cause of handicap acquired at adult âge and the second cause of dementia (Murray CJ, Lopez AD, Mortality by cause for eight régions of the world: Global Burden of Disease Study, Lancet, 1997; 349:1269-1276).
With CVA the vascular problem concerned is either thrombo-embolic (80% of CVAs) due to interrupted blood supply through obstruction of an artery, or hémorrhagie (20% of CVAs) through rupture of an artery. Cérébral thrombosis is most often caused by arteriosclerosis (hardening and inflammation of the vascular wall). Interrupted circulation secondary to arterial thrombosis (obstruction by a blood clôt) is the cause of infarction (death, necrosis of the région concerned)
accompanied by softening of the corresponding territory which is no longer irrigated. Gradually the dead tissue is replaced by conjunctive tissue formed of glial cells. Another cause of infarction is a brain embolism in which an atheroma plaque (fat) may detach itself from a large vessel, or when a blood clôt is formed for example in embolie cardiopathy (myocardial infarction, valvulopathy, arrhythmia through atrial fibrillation) and cornes to obstruct a cérébral artery causing an infarction. Brain hemorrhage may also be due to arteriosclerosis, most often accompanied by arterial hypertension. Brain hemorrhages may also be caused by congénital arterial malformation, infection, brain tumor, or even an upsetting event, an émotion or strenuous effort. Hemorrhage is the origin of hematoma formation which gradually résolves.
CVA diagnosis is firstly clinical. Examination of motor capacities and sensitivity of ail or part of the body directs diagnosis towards the site of the lésions which is confirmed by brain imaging. Diagnosis may give rise to problems in comatose, aphasie or amnésie patients. The seriousness of clinical signs varies from the lack of any notable sign to death within a period of a few days and may inciude motor, coordination and walking disorders, and disorders of sensitivity, speech, visual field, memory and psyché.
Treatment of CVA is started immediately after the event and takes into account the ischémie or hémorrhagie origin, determined by brain imaging using CT brain scans with or without contrast agent, and magnetic résonance imaging (MRI). To treat ischémie CVA the goal is to regulate hydroelectrolytic balance and arterial pressure and to obtain reperfusion of the injured territory using thrombolytic agents such as anti-platelet agents (aspirin) and fibrinolytics (e.g.
rt-PA (recombinant tissue plasminogen activator)) when the CVA is taken in charge less than 4h30 after the first signs. For hémorrhagie CVA, surgery is indicated if it is possible taking into account the topography and volume of the hematoma, the patient's level of consciousness and the acute phase, several months general condition. Recovery, after is very progressive and may take or years. It often requires réhabilitation to treat speech disorders. While motor disorders and/or walking (movernents) and sensory disorders (sensation) can generally be restored intellectuel sequels may be irréversible.
Traumatic brain injury (TBI) is the main cause of death and severe handicap before the âge of 45. The main causes are: road accidents (about 50%), sports accidents, occupational accidents, domestic accidents, attacks, natural disasters and acts of war. There are different types of TBI:
concussion: jarring of the brain subséquent to a violet blow to the brain, whether or not accompanied by initial or temporary loss of consciousness, with no visible radiological lésion to the brain. Return to consciousness spontaneously occurs after a few seconds, minutes or hours after the traumatic event in relation to the extent of the shock and may leave transient memory disorders, even secondary complications: extradural hematoma, sub-dural hematoma, cérébral edema.
brain contusion: in this case, there are anatomical lésions of the brain (hémorrhagie necrosis with edema), not necessarily at the site of impact, which may become complicated with brain edema.
immédiate deep coma: this is the most serious form of concussion. The patient is in a deep, persistent coma after the shock since the dysfunction of the ascending reticular activating System lies at
I
- i deeper depth. Signs of décérébration are possible indicating the presence of diffuse mesencephalic and axonal lésions related to concentric propagation and the concentration of the shock waves towards the centre of the brain (stereotaxic phenomena).
The management of TBI includes the search by brain imaging for surgically curable lésions (hematoma), surgery on opérable lésions or if not intensive care medical treatment in a specialized unit (anti-edema, pulmonary resuscitation etc.). Diuretics are used to reduce brain edema, and mannitol to dehydrate the brain tissue. At times brain edema is extensive enough to initiate brain herniation (engaging of the lower part of the brain underneath the faix cerebri towards the contralatéral cérébral hemisphere, engaging of the lower part of the brain into the foramen magnum) . Meningeal hemorrhage may also be associated with brain contusion, translating as headaches, stiff neck and alertness disorders. Clinical and radiological monitoring is set up after emergency treatment. Prognosis dépends on the extent of the initial lésions, patient âge and general condition before the event. The more the coma is superficial and the younger the patient in good health before the event the greater the chances of recovery. However coma may lead to brain death in some cases.
After the critical period following after the traumatic event and return to consciousness, as is the case with CVA, there is a period of functional recovery which may leave neurological sequels: signs of plegia or paralysis, balance disorders, symbol disorders of aphasia or agnosia type, signs of lésions to the cranial nerves; neuroendocrine disorders: diabètes insipidus, weight loss, fatigue, dizziness, loss of libido and impotency; mental disorders: anxiety after awareness of potentially irréversible sequels, anhedonia. Other conséquences are less frequent: subséquent post-traumatic epilepsy, vascular disorders such as aneurysm rupture or brain arterial thrombosis.
The field of the invention concerns medical action with the goal of improving recovery and functional réhabilitation after an acute neurological event whether a CVA or TBI. Within the context of the invention, improving recovery and functional réhabilitation means accelerating and amplifying the resolving of motor, neurophysiological, cognitive or psychiatrie symptoms whose onset occurred at the time of the neurological event, or one or more of these symptoms. According to the invention, the motor, neurophysiological, cognitive and psychiatrie symptoms include but are not limited to:
- paralysis and plegia, including hemiplegia and tétraplégie ;
- paresthesia or sensitivity disorders;
- coordination disorders, ataxia of the limbs and walking;
- eye movement disorders;
- swallowing disorders;
- speech disorders whether concerning perception and understanding or expression;
- apraxia and disrupted spatial orientation;
- sight disorders and disorders of the visual field;
- pupil anomalies;
- attention disorders;
- memory disorders affecting short-term memory (recent events) or long-term memory (past events;
- perception disorders, essentially visual concerning récognition of objects, images writing or physiognomies;
- disorders of executory functions such as action planning;
- anxiety;
- anhedonia and dépressive symptoms;
- perseverance;
- impulsiveness.
The invention also concerns recovery and functional réhabilitation after a récurrent neurological event occurring after an initial neurological event, caused by the conséquence thereof on postural balance, loss of sight or visuospatial neglect.
Studies in animal and man hâve shown that it is possible to accelerate or amplify functional recovery after an acute neurological event, via the administration of medical treatment immediately or even after a period of a few days to a few months following after the event. In animal models of unilatéral occlusion of the middle cérébral artery, which mimic CVA, and models of focal cortical lésions, which mimic TBI (Goldstein LB. Basic and clinical studies of pharmacological effects on recovery from brain injury, J. Neural Transplant & Plasticity, 1993, 4:175-192;
Feeney DM, de Smet AM, Rai S, Noradrenergic modulation of hemiplegia: facilitation and maintenance of recovery. Restor Neurol & Neurosci, 2004, 22:175-190), medical treatments which proved to be active in the rat and cat are:
- amphétamine, a product which increases extracellular levels of noradrenaline, serotonin and dopamine,
- transplantation of chromaffin cells, which secrete noradrenaline;
- intracérébral infusion of noradrenaline, but not serotonin or dopamine;
- administration of a noradrenaline precursor;
- administration of alpha-adrenergic agonists.
Clinical studies, in small groups of patients, hâve shown the possibility of improving motor recovery after CVA by treatment with amphétamine (Sonde L, Nordstrôm M, Nilsson CG, Lôkk J, Viitanen M, A doubleblind placebo-controlled study of the effects of amphétamine and physiotherapy after stroke. Cerebrovasc Dis, 2001,12:253-257); L-DOPS, a noradrenaline precursor (Nishino K, Sasaki T, Takahashi K, Chiba M, Ito T, The norepinephrine precursor L-threo-3,4dihydroxyphenylserine facilitâtes motor recovery in chronic stroke patients. J. Clin Neurosci, 2001, 8:547550), methylphenidate, an agent that also increases the extracellular rates of noradrenaline, serotonin and dopamine (Tardy J, Pariente J, Leger A, DechamontPalacin S, Gerdelat A, Guiraud V, Conchou F, Albucher JF, Marque P, Franceries X, Cognard C, Rascol 0, Chollet F, Loubinoux I, Methylphenidate modulâtes cérébral post-stroke reorganization, Neuroimage, 2006, 33 :913-922), reboxetine, a sélective inhibitor for the reuptake of noradrenaline (Zitel S, Weiller C, Liepert J, Reboxetine improves motor function in chronic stroke. A pilot study, J. Neurol, 2007, 254:197-201), fluoxetine, a sélective inhibitor for the reuptake of serotonin (Pariente J, Loubinoux I, Carel C, Albucher JF, Leger A, Manelfe C, Rascol O, Chollet F, Fluoxetine modulâtes motor performance and cérébral activation of patients recovering from stroke, Ann Neurol, 2001, 50:718-729). The effect of fluoxetine administered for 3 months was confirmed in a larger double-blind, * 1 , placebo-controlled clinical study (Chollet F, Tardy J, Albucher JF, Thalamas C, Berard E, Lamy C, Bejot Y, Deltour S, Jaillard A, Niclot P, Guillon B, Moulin T, Marque P, Pariente J, Arnaud C, Loubinoux I, Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomized placebo-controlled trial. Lancet Neurol, 2011, 10:123-30).
It is important to point out that these therapeutic approaches are not intended to restore or protect the injured brain area but to enable the brain which has some plasticity to reorganize its circuits to allow non-injured régions to ensure the functions normally carried out by the injured région, whether motor, neurophysiological or cognitive functions. This was confirmed by functional imagery after CVA and TBI. The ability of the monoamines (noradrenaline, serotonin, dopamine) to promote the functional reorganization of the brain tallies with their known neurotrophic rôle for developing neurons to ensure the différentiation and survival of neurons.
From these data showing the crucial rôle of serotonin and noradrenaline in functional recovery, it is concluded that a médicinal product which produces a rise in extracellular levels of both noradrenaline and serotonin would hâve an advantage over médicinal products which only increase serotonin levels, such as fluoxetine, for treatment after an acute neurological event.
Levomilnacipran is the (IS, 2R) enantiomer of milnacipran (Z (+)-2-aminomethyl)-N,N'-diethyl-1-phenyl cyclopropane carboxamide) described in patents WO 2004/075886 and WO 2009/127737. Milnacipran is an inhibitor of the reuptake of noradrenaline and serotonin having a balanced effect on these two neurotransmitters (Briley M, Prost JF, Moret C, 1 ,
Preclinical pharmacology of milnacipran. Int Clin Psychopharmacol, 1996 Suppl 4:9-14; Preskorn SH, Milnacipran: a dual norepinephrine and serotonin reuptake pump inhibitor, J Psychiatr Pract, 2004, 10:119-26). Milnacipran is a drug used in dépréssion (Spencer CM and Wilde MI, Milnacipran: a review of its use in dépréssion. Drugs, 1998, 56:405-427) and in fibromyalgie (Owen RT, Milnacipran hydrochloride: its efficacy, safety and tolerability profile in fibromyalgia syndrome. Drugs Today (Barc) 2008, 44:65360) . Patent applications WO2003/039598, W02003/068211,
W02003/077897,
W02004/030633,
W02003/090743,
W02004/045718,
W02004/009069,
WO/2007/038620,
WO2008/019388,
WO2008/021932 and WO2008/147843 also describe the use of milnacipran and its enantiomers in chronic fatigue syndrome, attention déficit with hyperactivity, viscéral pain syndromes, functional somatic syndromes, cognitive and sleep disorders, irritable bowel syndrome, chronic lumbar pain, chronic pelvic pain, interstitial cystitis, non-cardiac chest pain, neuropathie disorder, atypical multiple chemical pain, temporomandibular joint facial pain, tension headache, sensitivities, chronic pain associated with medical treatment or radiotherapy or other indications of chronic pain; in particular these patent applications do not describe the use of milnacipran for the treatment of CVA and TBI.
Levomilnacipran is the isomer deemed to be the active isomer of milnacipran; it has the highest affinity for noradrenaline and serotonin transporters compared with that of the other enantiomer, dextromilnacipran, and blocks the reuptake of noradrenaline and serotonin at lower concentrations than those required by dextromilnacipran (Example 1) . Surprisingly however dextromilnacipran is the most 4 ♦ powerful isomer on the alphal-adrenergic receptor in rat or man (Example 1). In addition, dextromilnacipran has alphal-antagonist behavior: it does not activate the recombinant human alphal receptor and antagonizes the effect of adrénaline (Example 2).
Preclinical and clinical data indicate that the alphal-adrenergic receptor plays a crucial rôle in functional recovery after a neurological event. Indeed a single administration of prazosin, a sélective antagonist of the alphal receptor (Hoffman and Lefkowitz, Catecholamines, sympathomimetic drugs and adrenergic receptor antagonists, in Goodman and Gilman's, The Pharmacological Basis of Therapeutics, Hardman JG, Limbird LE, Molinoff P B, Ruddon RW publishers, 9th édition, 1995, McGraw-Hill, New York, pp. 229) delays functional recovery after unilatéral focal traumatic contusion of the sensorimotor cortex in the rat (Feeney DM and Westerberg VS, Norepinephrine and brain damage: alpha noradrenergic pharmacology alters functional recovery after cortical trauma. Can J Psychology, 1990, 44: 233-252) and précipitâtes the reonset of motor symptoms in the rat up to 6 months after a unilatéral frontal lésion in the rat when motor functional recovery has been effective (Stibick DL and Fennec DM, Enduring vulnerability to transient reinstatement of hemiplegia by prazosin after traumatic brain injury, J. Neurotrauma, 2001, 18:303-312). In healthy volunteers, the administration of prazosin decreases the efficacy of motor training in inducing cérébral plasticity in the cortex, in the absence of any change in cortical-motor excitability (Sawaki L, Werhahn KJ, Barco R, Kopylev L, Cohen LG, Effect of an alphal-adrenergic blocker on plasticity elicited by motor training, Exp Brain Res, 2003, 148:504-508). Training-induced plasticity is assumed to contribute towards motor functional recovery after an acute neurological event. Goldstein et al (The influence of drugs on the recovery of sensorimotor function after stroke, J Neuro Rehab, 1990, 4:137-144) conducted a study in CVA patients and found that those who were prescribed drugs having deleterious effects on functional recovery in experimental animais, which notably included prazosin, had lower motor scores on the Fugl-Meyer scale than those not given these drugs with deleterious effects, over a 30-day prospective study following after inclusion. Ail these preclinical and clinical data show that an alphal-adrenergic antagonist must not be administered to a patient in functional recovery phase after an acute neurological event.
It has therefore surprisingly been discovered that it would be contra-indicated to administer dextromilnacipran, which was found to be an alphaladrenergic antagonist when developing the invention, to a patient in functional recovery after an acute neurological event whether a CVA or TBI. Therefore contrary to the provision made in application W02006/006617, the milnacipran racemate which contains an equal proportion of levomilnacipran and dextromilnacipran, must not be prescribed in the abovementioned clinical situations. On the contrary, substantially pure levomilnacipran or a levomilnacipran/dextromilnacipran mixture containing dextromilnacipran in a proportion not exceeding 5% by weight of the said mixture (see Example 3) should be used during functional recovery after an acute neurological event whether a CVA or TBI.
Patent W02004/075886 claims the use of levomilnacipran to préparé a médication for a variety of pathologies in patients presenting with t , cardiovascular risk, on the basis of the observation that levomilnacipran induces fewer hémodynamie phenomena than the milnacipran racemate in dogs. However, this patent does not disclose the particular activity of dextromilnacipran on the alphal-adrenergic receptor and even less so the use of levomilnacipran for functional recovery after CVA or TBI.
Further, according to the invention, levomilnacipran is used in the form of a pharmaceutically acceptable sait chosen from among the inorganic acid addition salts non-toxic for patients in whom they are administered. The term pharmaceutically acceptable refers to molecular entities and compositions which do not produce any adverse or allergie effect or other undesirable reaction when administered to man or animal. Examples of pharmaceutically acceptable acid addition salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, palmitate, lactate, nitrate, acetate, oxalate, valerate, oleate, stéarate, laurate, borate, citrate, benzoate, fumarate, the like
Monkhouse maleate, and tosylate, tartrate, naphthylate salts Bighley 66:1-19). invention phosphate, succinate, (see for example Berge SM, DC, Pharmaceutical salts, 1977, sait however in the présent preferred levomilnacipran hydrochloride.
The invention also concerne a
LD,
The is pharmaceutical composition characterized in that it contains levomilnacipran as active ingrédient and at least one pharmaceutically acceptable excipient. When used herein, the term pharmaceutically acceptable excipient includes any diluent, adjuvant or excipient such as preserving agents, filler agents, disintegrating, wetting, emulsifying, dispersing, antibacterial or antifungal agents, or agents which can delay intestinal and digestive absorption and résorption. The use of these media or vectors is well known to the person skilled in the art.
The pharmaceutical compositions may contain substantially pure levomilnacipran or mixtures of levomilnacipran and dextromilnacipran, provided that the proportion of dextromilnacipran is insufficient for the alphal-adrenergic antagonist activity to be significant and for the patient to be exposed to 10 blocking of the alphal-adrenergic receptor. A simulation of the activity of the levomilnacipran/dextromilnacipran mixtures, confirmed by experimental data, shows that the anti-alphal activity becomes significant with mixtures containing 15 more than 5% of dextromilnacipran {Example 3) . The proportion of dextromilnacipran in a levomilnacipran/dextromilnacipran mixture must not therefore exceed 5% by weight of the said mixture.
The pharmaceutical compositions according to the 20 présent invention can be formulated for administration to mammals, including man. The compositions of the invention can be administered via oral, sublingual, sub-cutaneous, intramuscular, intravenous, transdermal, local or rectal route. In this case, the active 25 ingrédient can be administered in unit administration forms, in a mixture with conventional pharmaceutical carriers, to animal or human beings. The suitable unit administration forms comprise the forms via oral route such as tablets, capsules, powders, granules, each 30 containing a predetermined quantity of levomilnacipran, they also include oral solutions or suspensions in an aqueous liquid or non-aqueous liquid, or an oil/water or water/oil liquid émulsion, sublingual and mouth administration forms, sub-cutaneous or transdermal, 35 topical, intramuscular, intravenous, intra-nasal or
* intraocular administration forms and rectal administration forms. When a solid composition is prepared in tablet form, the levomilnacipran is mixed with a pharmaceutical vehicle such as gelatin, starch, lactose, magnésium stéarate, talc, gum Arabica, silica or the like. It is possible to coat the tablets with sucrose or other suitable materials.
The release of the said active ingrédient can be delayed to obtain sustained release so as to allow the administration of a single daily dose. Said galenic formulation can be obtained following the method described in patent EP 939 626 or any other method.
A capsule préparation is obtained by mixing the active ingrédient with a diluent and pouring the mixture obtained into soft or hard capsules.
A préparation in syrup or élixir form can contain the active ingrédient combined with a sweetener, an antiseptie, and a suitable flavoring agent and coloring agent.
Powders or water-dispersible granules can contain the active ingrédient in a mixture with dispersing or wetting agents, or suspending agents, and also with flavor enhancing or sweetening agents.
For rectal administration, recourse is had to suppositories prepared with binders melting at rectal température e.g. cocoa butter or polyethylene glycols.
For parentéral administration (intravenous, intramuscular, intradermal, sub-cutaneous), intra-nasal or intra-ocular administration, aqueous suspensions are used, isotonie saline solutions or stérile solutions for injection which contain pharmaceutically compatible dispersing and/or wetting agents.
The active ingrédient may also be formulated in the form of microcapsules optionally with one or more additive carriers.
Advantageously the pharmaceutical composition according to the présent invention is intended for administration via oral route.
The dosages of the pharmaceutical compositions containing levomilnacipran in the compositions of the invention are adjusted to obtain a quantity of active substance which is efficient to obtain the desired therapeutic response for a composition particular to the administration route. The chosen dosage level therefore dépends on the desired therapeutic effect, the chosen route of administration, the desired length of treatment, the weight, âge and gender of the patient, the sensitivity of the individual to be treated. As a resuit, the optimal dosage must be determined in relation to parameters deemed to be relevant by specialists in the field.
Preferably the levomilnacipran is administered in pharmaceutically acceptable compositions in which the daily dose of levomilnacipran, expressed as base amount, is between 25 and 200 mg taken in a single administration or several times per day. Further preferably, the pharmaceutical composition allows modified intestinal absorption so that a single administration per day is sufficient.
Example 1
Measurement of the affinity of the two isomers of milnacipran for the noradrenaline and serotonin transporters and for the alphal-adrenergic receptor.
The affinities of levomilnacipran and dextromilnacipran were measured on the binding to the recombinant human transporters of noradrenaline and serotonin, and on the binding to the human recombinant alphal receptor. The inhibition by these two products of the reuptake of noradrenaline [3H] and serotonin [3H] was also measured.
Methods:
Binding to the noradrenaline transporter: binding was measured on membranes of MDCK cells expressing this transporter, purchased from Perkin-Elmer (batch N° 418-165-A), diluted in 50 mM TRIS-HC1 buffer containing 120 mM NaCL and 5 mM KC1 at a concentration of 5 pg proteins, in the presence of 2 mM N-methyl-nisoxetine [3H] and increasing concentrations of levomilnacipran or dextromilnacipran ( 10-u to ΙΟ-5 M) . The bound fraction was separated by filtration and washing in cooled TRIS + NaCl + KC1 buffer. Non-specific binding was measured in the presence of 10 μΜ desipramine.
Binding to measured on the serotonin transporter: binding was membranes of MDCK cells expressing this purchased from diluted in 50 transporter,
N° 316-199-A) containing 120 mM NaCl concentration of 5 μg of of 2 nM citalopram of ( 10'11 separated + NaCl
Perkin-Elmer
TRIS-HC1 mM (Batch buffer and nM concentrations dextromilnacipran fraction was cooled TRIS binding was fluoxetine.
measured by +
mM
KC1 at a the presence increasing or to 10° M) . The bound filtration and washing in KC1 buffer. Non-specific of 10 μΜ in and proteins, [3H] levomilnacipran 10’5 in the presence
Binding to the recombinant human alphal receptor: binding was measured on membranes of CHO cells (Chinese Hamster Ovary) expressing the human alphalB receptor (Wurch T, Boutet-Robinet EA, Palmier C, Colpaert FC, Pauwels PJ, Constitutive coupling of chimeric dopamine D2/alphalB receptor to the
* phospholipase C pathway: inverse agonism to silent antagonism of neuroleptic drugs, J Pharmacol Exp Ther, 2003, 304:380-390) diluted in 50 mM TRIS-HCI buffer at a concentration of 7.8 pg of proteins, in the presence of 0.1 nM prazosin [3H] and increasing concentrations of levomilnacipran or dextromilnacipran (10u to ΙΟ-5 M) . The bound fraction was separated by filtration and washing in cooled TRIS buffer. Non-specific binding was measured in the presence of 10 pM phentolamine. Reuptake of noradrenaline [3H]: CHO-K1 cells were permanently transfected with the gene of the human transporter of noradrenaline by electric pulsing (Biorad gene puiser) and the transfected clones were then selected by incubation in geneticin. To measure reuptake, the transfected cells were cultured in 24well plates then incubated in the presence of pargyline and ascorbate (100 pM) and noradrenaline [3H] (spécifie activity = 40.7 Ci/mole) at a concentration of 10 nM. Reuptake was halted by aspiration and rinsing the medium and the radioactivity captured by the cells was counted by liquid scintillation. The non-specific signal was determined in the presence of 10 pM desipramine.
Reuptake of serotonin [3H]: CHO-K1 cells were transfected permanently with the gene of the human transporter of serotonin by electric pulsing (Biorad gene puiser) and the transfected clones were selected by incubation in geneticin. To measure reuptake, the transfected cells were cultured in 24well plates then incubated in the presence of pargyline and ascorbate (100 pM) and serotonin[3H] (spécifie activity = 32.7 Ci/mole) at a concentration of 10 nM. Reuptake was halted by aspiration and rinsing of the medium and the captured radioactivity by the cells was counted by liquid scintillation. The non-specific signal was determined in the presence of 10 μΜ fluoxetine.
Résulte :
Table 1 gives the values of inhibition constants (Ki) of levomilnacipran and dextromilnacipran for the serotonin and noradrenaline transporters, and of the alphal-adrenergic receptor.
Table 1
Value of Ki for binding or of IC50 for reuptake (μΜ) | ||
Target | levomilnacipran | dextromilnacipran |
Binding to the noradrenaline transporter (NET) | 0.091 | 10.5 |
Binding to the serotonin transporter (SERT) | 0.011 | 0.32 |
Inhibition of noradrenaline reuptake [3H] | 0.010 | 0.15 |
Inhibition of serotonin reuptake [3H] | 0.018 | 0.28 |
alA adrenergic receptor | 110 | 3.4 |
Example 2
Measurement of the intrinsic activity of dextromilnacipran on recombinant human alphalA and 15 alphalB receptors.
The intrinsic functional activity of dextromilnacipran was measured on cells expressing the
human alphalA and alphalB receptors to détermine the agonist/antagonist property thereof.
Methods:
CHO-K1 cells having stable expression of the human alphalA receptor or human alphalB receptor were obtained using the described method (Vicentic et al. Biochemistry and pharmacology of epitope-tagged alphala-adrenergic receptor subtype, J Pharm Exp Ther, 2002, 302-58-65). The agonist activity was evaluated by fluorimetry measurement of the intracellular concentration of calcium following a conventional technique using a fluorescent calcium chelator and signal recording with a Fluorometric Imaging Plate Reader (FLIPR, Molecular Devices, Saint-Grégoire, France). As positive reference (-) adrénaline was used, and responses were then normalized to the response of (-)adrénaline at a concentration of 10 μΜ.
Results:
Over a concentration range of 3.107 M to 10-3 M, dextromilnacipran did not show any agonist activity higher than 10% of the activity of the (-) adrénaline, whether on the alphalA receptor or alphalB receptor. The (-)adrénaline was then incubated in increasing concentrations (3.10-10 to 3.105 M) in the presence of levomilnacipran or dextromilnacipran at a concentration of 300 μΜ. Figure 1 shows that the concentrationresponse curve of the (-)adrénaline is shifted towards the right by dextromilnacipran by a factor of about 100 for the alphalA sub-type and by about 10 for the alphalB sub-type. For levomilnacipran, the shift is only about 3 for the alphalA sub-type and 2 for the alphalB sub-type. It is concluded that dextromilnacipran is an antagonist for these two subtypes of alphal-adrenergic receptors. Levomilnacipran is also an antagonist of the alphalA and alphalB
much less powerful extent than characteristics of dextromilnacipran, mixtures with of varying has a racemic IR, 2S enantiomer is the most active binding with the binding with the
2R) receptors but to a dextromilnacipran.
Example 3
Pharmacological levomilnacipran and proportions of the enantiomers.
Objectives
Levomilnacipran (enantiomer, IS, distinct pharmacological profile compared with milnacipran (2207) and the other (dextromilnacipran). Levomilnacipran enantiomer on the desired targets: noradrenaline transporter (NET), serotonin transporter (SERT) and the PCP site (NMDA receptor, glutamate System), but is the least active on non-desired targets i.e. on alA and alB adrenergic receptors. We estimated the pharmacological properties of different mixtures (containing varied percentages of dextromilnacipran). First, binding assays were simulated and the apparent inhibition constants of the mixtures for NET, SERT and the alA receptors were calculated. Next, the simulation was experimentally
validated for the | alA receptors for | which | the |
variations in levomilnacipran had the most | impact. | ||
Methods | |||
Simulation | |||
The inhibition | constants (value | of Ki) | of |
levomilnacipran and | dextromilnacipran on the | main |
targets were experimentally determined using conventional binding assays with spécifie radioligands and recombinant human proteins (see Example 1).
For each target, the total of bound radioligand was calculated taking into account the inhibitor effect of each inhibitor. The total of each occupied target is described using the conventional law of mass action:
* (1) R.S. = Kd
B (2) R, li = Kn
RIi (3) R.I2 = Ki2
RIZ (4) Bmax = B + RIX + RI2 + R where R is the concentration of free binding sites; Bmax is the total concentration of sites; B is the concentration of sites bound to the radioligand; S is the radioligand concentration; Kd is the dissociation constant of the radioligand; ix is the concentration of inhibitor 1; Kn is the inhibition constant of inhibitor 1; RIX is the concentration of sites occupied by inhibitor 1; i2 is the concentration of inhibitor 2; Ki2 is the inhibition constant of inhibitor 2 and RI2 is the concentration of sites occupied by inhibitor 2.
On the basis of équations (1) to (4):
Bmax.S
B =
S + Kd | (1 + ix/KiX + I2/Ki2) | ||||
The | values | of | B | were calculated | taking into |
account | the real | values | of Kn and Ki2 (see | Table above) |
causing the proportion of dextromilnacipran to vary by 0.01% to 30% in the mixture, and varying the concentration of the mixture from 0.01 to 52.0 μΜ. The values of Kd and S which were used were similar to the values of the binding assays. A theoretical inhibition
curve was therefore plotted with each combination of values of the different parameters. Then the apparent IC50 value for each curve was calculated by non-linear régression as per the logistic équation:
Y = 100/1 + 10 (i-LogICso) where i is the concentration of the inhibitor (mixture) and the apparent value of K± was derived using the Cheng-Prussoff équation: IC50 - Κι (1 + S/Kd) .
2.2 Binding assays
A sériés of levomilnacipran and dextromilnacipran mixtures with varying proportions of dextromilnacipran was prepared, and each mixture was incubated at varying concentrations with membranes of cells expressing the recombinant human alA receptor and using prazosin[3H] as radioligand. The apparent IC50 value for each curve was calculated by non-linear régression as per the logistic équation:
Y = 100/1 + 10 (i-LogIC5o) where i is the concentration of the inhibitor (mixture) and the apparent value of Ki was derived using the Cheng-Prussoff équation: IC50 = K± (1 + S/Kd) .
Results
The results are expressed as apparent Ki value as a function of dextromilnacipran percentage (Figure 1).
Figure 2 shows: the apparent Κχ values of simulated assays (A, B and C) and measured values (D) of mixtures of levomilnacipran (F2695) and dextromilnacipran (F2696) with increasing proportions of dextromilnacipran for NET, SERT or alA receptor targets.
The values of Ki for NET and SERT were not too affected by different proportions of dextromilnacipran. On the contrary, the apparent value of Ki for the alA <·« V « receptors, whether for simulation assays or for real assays, was dramatically affected when the percentage of dextromilnacipran was increased, which indicates that the impact on the al receptors is non-negligible.
If it is considered that the impact becomes nonnegligible when the value of Kl drops by half, the maximum percentage of dextromilnacipran is about 5%.
Conclusion
A mixture with a proportion of dextromilnacipran higher than this 5% may not be bioequivalent to substantially pure levomilnacipran, or to a mixture with smaller proportions of dextromilnacipran. The impact on the alA receptors of mixtures with proportions of dextromilnacipran higher than 5% is not negligible and such mixtures should not be used in the treatment of functional recovery after a stroke.
Claims (8)
1. A levomilnacipran/dextromilnacipran mixture containing dextromilnacipran in a proportion not exceeding 5% by weight of the said mixture for use thereof as médicinal product for recovery and functional réhabilitation after an acute neurological event and récurrences thereof.
2. The mixture according to claim 1 for use thereof in patients diagnosed with cérébral vascular accident of ischémie or hémorrhagie origin.
3. The mixture according to claim 1 for use thereof in patients diagnosed with traumatic brain injury.
4. Pharmaceutical compositions comprising at least one pharmaceutically acceptable excipient and a levomilnacipran/dextromilnacipran mixture containing dextromilnacipran in a proportion not exceeding 5% by weight of the said mixture as active ingrédient for use thereof as médicinal product for recovery and functional réhabilitation after an acute neurological event and récurrences thereof.
5. Pharmaceutical compositions according to claim 4 in patients diagnosed with cerebrovascular accident.
6. Pharmaceutical compositions according to claim 4 in patients diagnosed with traumatic brain injury.
7. Pharmaceutical compositions according to any of of the daily claims 4 to 6 characterized in that levomilnacipran is between 50 and 200 mg.
Pharmaceutical compositions according
4 to 7 characterized in that they are in a intestinal absorption form allowing the dosage
8.
claims to one of modified administration of a single dose per day.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1156917 | 2011-07-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA16854A true OA16854A (en) | 2016-01-07 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018250214B2 (en) | Methods and compositions for treating aging-associated impairments using CCR3-inhibitors | |
BR112020006105A2 (en) | cannabidiol in combination with a 5-ht2b receptor agonist, an amphetamine or an amphetamine derivative, and method for treating epilepsy | |
Lauterbach | An extension of hypotheses regarding rapid-acting, treatment-refractory, and conventional antidepressant activity of dextromethorphan and dextrorphan | |
JP2010531879A (en) | Drug showing anxiolytic action based on hydrogenated pyrido [4,3-b] indole, pharmacological compound thereof and method of application | |
JP6887462B2 (en) | Composition of 2,4,6-trifluoro-N- [6- (1-methyl-piperidine-4-carbonyl) -pyridin-2-yl] -benzamide | |
EA010430B1 (en) | Combination of an nmda receptor antagonists and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders | |
JP2011148799A (en) | New use of 1-[4-(5-cyanoindol-3-yl) butyl]-4 -(2-carbamoyl-benzofuran-5-yl)-piperazine and physiologically acceptable salt thereof | |
AU2019257499A1 (en) | Method for preventing and/or treating chronic traumatic encephalopathy-II | |
Tatarczyñska et al. | Effects of combined administration of 5-HT~ 1~ A and/or 5-HT~ 1~ B receptor antagonists and paroxetine or fluoxetine in the forced swimming test in rats | |
Zesiewicz et al. | Drug-induced hyperkinetic movement disorders by nonneuroleptic agents | |
OA16854A (en) | Levomilnacipran drug for functional rehabilitation after an acute neurological stroke | |
US20140179794A1 (en) | Levomilnacipran-based drug for functional recovery after acute neurological events | |
NZ621474B2 (en) | Levomilnacipran drug for functional rehabilitation after an acute neurological stroke | |
AU2015258814B2 (en) | Clearance of amyloid ss | |
Baizabal-Carvallo et al. | The pharmacological treatment of Tourette syndrome | |
CN111032048B (en) | Use of buspirone for the treatment of functional dizziness | |
CN100469368C (en) | Use of adatanserin for treating neurogenerative disorders | |
Guillaume | Characterization of the neurokinin3-and histamine2-receptors in brown and white adipose tissue | |
WO2020069008A1 (en) | Methods and compositions for treating aging-associated impairments using ccr3-inhibitors | |
EA041007B1 (en) | USE OF BUSPIRONE FOR THE TREATMENT OF FUNCTIONAL VERTIGO |